-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NMaf9PqLROP/g+ithOaPPfIW3ADmxdjfqpFnB1Rm9od1r3PifBxrn+ux1LNjD0vp V//chvXSIs/jFiLnXezYPA== 0001317757-10-000020.txt : 20100806 0001317757-10-000020.hdr.sgml : 20100806 20100806160028 ACCESSION NUMBER: 0001317757-10-000020 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100805 FILED AS OF DATE: 20100806 DATE AS OF CHANGE: 20100806 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arkowitz David CENTRAL INDEX KEY: 0001296999 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-10865 FILM NUMBER: 10998405 MAIL ADDRESS: STREET 1: C/O IDENIX PHARMACEUTICALS, INC. STREET 2: 60 HAMPSHIRE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMAG PHARMACEUTICALS INC. CENTRAL INDEX KEY: 0000792977 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 042742593 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02140 BUSINESS PHONE: 6174972070 MAIL ADDRESS: STREET 1: 100 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02140 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED MAGNETICS INC DATE OF NAME CHANGE: 19920703 4 1 primary_doc.xml PRIMARY DOCUMENT X0303 4 2010-08-05 0 0000792977 AMAG PHARMACEUTICALS INC. AMAG 0001296999 Arkowitz David C/O AMAG PHARMACEUTICALS, INC. 100 HAYDEN AVENUE LEXINGTON MA 02421 0 1 0 0 EVP, CFO and CBO Common Stock 2010-08-05 4 C 0 15000 A 16886 D Common Stock 2010-08-05 4 S 0 15750 D 1136 D Restricted Stock Unit 2010-08-05 4 C 0 15000 A Common Stock 15000 15000 D The shares were acquired by the reporting person as a result of the partial vesting of a restricted stock unit grant described below. Not applicable. The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading pan adopted by the reporting person. The shares sold on this date were sold in multiple transactions. The price is the weighted average sales price per share of all shares sold on this day. The actual sales prices range from $31.387-$31.90. Upon request by the Securities and Exchange Commission, the issuer, or any security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each price. Each restricted stock unit represents a contingent right to receive one share of common stock. Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. The grant will vest as follows: 50% on August 5, 2010, 25% on August 5, 2011 and the remaining 25% on August 5, 2012. Joseph L. Farmer, attorney-in-fact 2010-08-06 -----END PRIVACY-ENHANCED MESSAGE-----